1 results match your criteria: "Lundquist Research Institute for Biomedical Innovation at Harbor-UCLA Medical Center[Affiliation]"
Risk of Subsequent Breast Cancer in Women with Early Stage HER2-Positive Breast Cancer in a Large Community Health Plan.
Breast Cancer (Dove Med Press)
August 2023
Lundquist Research Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA.
Purpose: Clinical outcomes have improved for women with early stage, HER2-positive breast cancer following the FDA approval of adjuvant trastuzumab use in 2006. However, only limited information exists on such patients' outcomes in real-world settings outside of clinical trials. We examined the risk of subsequent breast cancer in women with HER-2 positive disease, and the impact of trastuzumab use, in a large California community-based health plan.
View Article and Find Full Text PDF